The procedure was performed on Wednesday, May 13, 2015 at Tufts Medical Center by surgeon Sajani Shah, MD. The surgery proceeded without incident and the patient returned home on the same day as the surgery, is recovering well and has returned to work full-time.
"Until recently, there was a great unmet need for new, alternative treatment options for obese patients for whom behavior modification, pharmaceutical options or anatomy altering/restricting surgical procedures either did not work, or were not viable options," said Dr. Shah. "Earlier this year, the FDA approved a first-of-its-kind treatment that offers a neuroscience-based approach to the treatment of obesity, differentiating it from traditional weight loss surgical options. As a member of the team that brought this new device through the clinical trial phase, I am pleased to have performed the first US commercial implant of vBloc Therapy. At Tufts Medical Center, we are committed to staying on the leading edge of new technologies that may benefit our patients."
vBloc Therapy intermittently blocks intra-abdominal vagus nerve signaling, or transmission of messages involving food intake and processing, between the brain and stomach using a pacemaker-like implant called the Maestro® Rechargeable System. In January of this year, the system was approved for adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years.
"The first commercial implant of vBloc Therapy marks another significant milestone for EnteroMedics and the millions of individuals with obesity who may be seeking different ways of achieving safe, effective weight loss," said Mark B. Knudson, PhD, President and Chief Executive Officer of EnteroMedics. "We are pleased with the response to vBloc Therapy from patients and physicians alike and remain focuse
ST. PAUL, Minn., May 20, 2015 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the first ever commercial implant of the Maestro® Rechargeable System, delivering vBloc® Neurometabolic Therapy, in the United States.